Biologics in Inflammatory Bowel Disease, An issue of Gastroenterology Clinics of North America, 1st Edition
Author :
Edward V. Loftus Jr
By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we c ...view more
By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we come a long way in understanding the efficacy and safety of infliximab, we are beginning to understand how and when to use the drug. Furthermore, as of this writing, we have five other biologic agents approved for either Crohn disease or ulcerative colitis, and there are many more molecules currently in drug development for these indications. In this issue,the Editors have assembled a collection of experts to provide the most cutting-edge information on the status of biologic therapy for inflammatory bowel disease.
By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we come a long way in understanding the efficacy and safety of infliximab, we are beginning to understand how and when to use the drug. Furthermore, as of this writing, we have five other biologic agents approved for either Crohn disease or ulcerative colitis, and there are many more molecules currently in drug development for these indications. In this issue,the Editors have assembled a collection of experts to provide the most cutting-edge information on the status of biologic therapy for inflammatory bowel disease.
Author Information
By Edward V. Loftus Jr, MD, Mayo Clinic, Rochester, MN
https://www.us.elsevierhealth.com/biologics-in-inflammatory-bowel-disease-an-issue-of-gastroenterology-clinics-of-north-america-9780323323253.html1369Biologics in Inflammatory Bowel Disease, An issue of Gastroenterology Clinics of North Americahttps://www.us.elsevierhealth.com/media/catalog/product/9/7/9780323323253.jpg74.2498.99USDInStock/Medicine/Gastroenterology/Clinics/Clinics1174388725525504113841826925145120<p>By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we come a long way in understanding the efficacy and safety of infliximab, we are beginning to understand how and when to use the drug. Furthermore, as of this writing, we have five other biologic agents approved for either Crohn disease or ulcerative colitis, and there are many more molecules currently in drug development for these indications. In this issue,the Editors have assembled a collection of experts to provide the most cutting-edge information on the status of biologic therapy for inflammatory bowel disease.</p> <p>By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we come a long way in understanding the efficacy and safety of infliximab, we are beginning to understand how and when to use the drug. Furthermore, as of this writing, we have five other biologic agents approved for either Crohn disease or ulcerative colitis, and there are many more molecules currently in drug development for these indications. In this issue,the Editors have assembled a collection of experts to provide the most cutting-edge information on the status of biologic therapy for inflammatory bowel disease.</p>00add-to-cart97803233232532014ProfessionalBy Edward V. Loftus Jr, MD20141Book152w x 229h (6.00" x 9.00")Elsevier0Aug 12, 2014IN STOCK - This may take up to 5 business days to shipBy <STRONG>Edward V. Loftus Jr</STRONG>, MD, Mayo Clinic, Rochester, MNClinicsClinicsThe Clinics: Internal MedicineNoNoNoNoPlease SelectPlease SelectPlease Select
